Get to know our clinical trials
Phase 3 clinical trial comparing rituximab plus zanubrutinib with rituximab monotherapy in previously untreated symptomatic splenic marginal zone lymphoma
THE AIM OF THIS CLINICAL TRIAL IS TO COMPARE THE EFFICACY AND TOLERABILITY OF THE COMBINATION OF TWO DRUGS, RITUXIMAB AND ZANUBRUTINIB, COMPARED TO RITUXIMAB MONOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) REQUIRING SYSTEMIC TREATMENT.
Technical Summary
- PHASE 3, RANDOMIZED, UNCONCEALED, MULTICENTER, INTERVENTIONAL, MULTICENTER STUDY COMPARING RITUXIMAB PLUS ZANUBRUTINIB TO RITUXIMAB MONOTHERAPY IN PREVIOUSLY UNTREATED SYMPTOMATIC MARGINAL ZONE SPLENIC LYMPHOMA
- Code EudraCT: 2023-503755-10-00
- Protocol number: IELSG48
- Promoter: International Extranodal Lymphoma Study Group (IELSG)
- Molecule/Drug: Rituximab/Zanubrutinib
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.